Genentech, together with City of Hope, has filed a new complaint for patent infringement against Pfizer over PF-06439535, Pfizer’s proposed bevacizumab biosimilar referencing Genentech’s Avastin.
Genentech, together with City of Hope, has filed a new complaint for patent infringement against Pfizer over PF-06439535, Pfizer’s proposed bevacizumab biosimilar referencing Genentech’s Avastin.
The complaint, filed in the United States District Court for the District of Delaware, claims that Pfizer has infringed on 22 patents related to bevacizumab and comes after Pfizer submitted an abbreviated Biologics License Application (aBLA) for the product to the FDA.
According to the complaint, Pfizer had 20 days to provide Genentech with its aBLA after regulatory submission, and the biosimilar developer was also required to provide “other information” related to manufacturing of the proposed product. This early disclosure under the terms of the Biologics Price Competition and Innovation Act (BPCIA), says Genentech, is important for the undertaking of preliminary injunction proceedings.
However, according to the complaint, Pfizer “ignored this targeted request” for information and “took the position that producing only portions of its aBLA alone was sufficient under the statute.” In September of last year, Pfizer produced “only portions” of the aBLA and did not give Genentech the other information that it sought.
Despite Genentech’s protests, Pfizer has indicated that its production satisfied statutory obligations, leading to an exchange of correspondence between the drug makers over the following months.
In March 2019, Pfizer accepted and agreed on the patents, for which Genentech provided infringement contentions, that would be the subject of a patent infringement action under the BPCIA.
Some of the patents listed in the complaint have already expired, but Genentech contends that, prior to expiry, Pfizer infringed these patents by making its proposed biosimilar in the United States in a manner not covered by safe harbor.
Genentech has requested a trial by jury. It has asked that the court find that Pfizer has infringed on its asserted patents and will infringe on those patents by making, using, or selling its product, and it also asks that the court find that Pfizer failed to provide adequate information as required under law. Genentech seeks damages, including a preliminary and a permanent injunction against infringement of the patents in question.
Escaping the Void: All Things Biosimilars With Craig & G
May 4th 2025To close out the Festival of Biologics, Craig Burton and Giuseppe Randazzo from the Association for Accessible Medicines and the Biosimilars Council tackle the current biosimilar landscape and how the industry can emerge from the "biosimilar void."
Eye on Pharma: Sandoz Files Antitrust Suit; Yuflyma Interchangeability; Costco’s Ustekinumab Pick
April 22nd 2025Sandoz's antitrust suit against Amgen, the FDA’s interchangeability designation for Celltrion’s adalimumab biosimilar, and the inclusion of an ustekinumab biosimilar in Costco’s prescription program highlight growing momentum to expand biosimilar access and affordability for patients with chronic inflammatory diseases.
Will the FTC Be More PBM-Friendly Under a Second Trump Administration?
February 23rd 2025On this episode of Not So Different, we explore the Federal Trade Commission’s (FTC) second interim report on pharmacy benefit managers (PBMs) with Joe Wisniewski from Turquoise Health, discussing key issues like preferential reimbursement, drug pricing transparency, biosimilars, shifting regulations, and how a second Trump administration could reshape PBM practices.
President Trump Signs Executive Order to Bring Down Drug Prices
April 16th 2025To help bring down sky-high drug prices, President Donald Trump signed an executive order pushing for faster biosimilar development, more transparency, and tougher rules on pharmacy benefit managers—aiming to save billions and make meds more affordable for everyone.
How State Substitution Laws Shape Insulin Biosimilar Adoption
April 15th 2025States with fewer restrictions on biosimilar substitution tend to see higher uptake of interchangeable insulin glargine, showing how even small policy details can significantly influence biosimilar adoption and expand access to more affordable insulin.